Zai Lab Limited

32.04
-1.76 (-5.21%)
At close: Apr 25, 2025, 3:59 PM
32.35
0.97%
Pre-market: Apr 28, 2025, 08:36 AM EDT
-5.21%
Created with Highcharts 11.4.39 AM4 PM10 AM12 PM1 PM2 PM323334
Bid 31.11
Market Cap 351.28M
Revenue (ttm) 398.99M
Net Income (ttm) -257.1M
EPS (ttm) -2.6
PE Ratio (ttm) -12.32
Forward PE 120.83
Analyst Buy
Ask 32.35
Volume 1,204,376
Avg. Volume (20D) 1,375,181.1
Open 33.18
Previous Close 33.80
Day's Range 31.70 - 33.20
52-Week Range 15.65 - 39.77
Beta 1.09

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and ...

Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 1,869
Stock Exchange NASDAQ
Ticker Symbol ZLAB
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for ZLAB stock is "Buy." The 12-month stock price forecast is $51, which is an increase of 59.18% from the latest price.

Created with Highcharts 11.4.3StrongSellSellHoldBuyStrongBuy02413
Price Target: $51
(59.18% upside)
Analyst Consensus: Buy
Stock Forecasts

Next Earnings Release

Zai Lab Limited is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+6.69%
Zai Lab shares are trading higher on possible cont... Unlock content with Pro Subscription
1 month ago
+5.7%
Zai Lab shares are trading higher after JP Morgan raised its price target on the stock from $44 to $51.